These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22643704)

  • 1. Metastatic bladder cancer: anything new?
    Calabrò F; Sternberg CN
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):304-9. PubMed ID: 22643704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
    Wallerand H; Reiter RR; Ravaud A
    Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.
    Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG
    Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
    Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
    Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment of metastatic bladder cancer and future directions.
    Lei AQ; Cheng L; Pan CX
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1851-62. PubMed ID: 22117153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving role of chemotherapy in advanced urothelial cancer.
    Calabrò F; Sternberg CN
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):180-6. PubMed ID: 18685360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New molecular targets and novel agents in the treatment of advanced urothelial cancer.
    Beekman KW; Bradley D; Hussain M
    Semin Oncol; 2007 Apr; 34(2):154-64. PubMed ID: 17382799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of long-term treatment of inoperable cancer of the bladder with cisplatin and concurrent irradiation: prognostic factors of local control and survival].
    Chauvet B; Félix-Faure C; Davin JL; Choquenet C; Alfonsi M; Reboul F
    Cancer Radiother; 1998 Apr; 2 Suppl 1():85s-91s. PubMed ID: 9749086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonplatinum therapy in advanced bladder cancer.
    Srinivas S; Colocci N
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):887-94. PubMed ID: 16761932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for urothelial carcinoma.
    Gartrell BA; Sonpavde G
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
    Ortmann CA; Mazhar D
    Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on chemotherapy for advanced bladder cancer.
    Rosenberg JE; Carroll PR; Small EJ
    J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small cell bladder cancer: biology and management.
    Fahed E; Hansel DE; Raghavan D; Quinn DI; Dorff TB
    Semin Oncol; 2012 Oct; 39(5):615-8. PubMed ID: 23040258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
    Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
    Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
    Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
    Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
    Stenzl A; Cowan NC; De Santis M; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
    Eur Urol; 2011 Jun; 59(6):1009-18. PubMed ID: 21454009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic chemotherapy in regionally advanced bladder cancer. Theoretical considerations and results.
    Scher HI
    Urol Clin North Am; 1992 Nov; 19(4):747-59. PubMed ID: 1441029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and therapeutic applications of the molecular events in clinical management of urothelial carcinoma of bladder.
    Garg M
    J Exp Ther Oncol; 2014; 10(4):301-16. PubMed ID: 25509986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment strategies for metastatic patients in bladder cancer].
    Théodore C
    Bull Cancer; 2010; 97 Suppl Cancer de la vessie():27-33. PubMed ID: 20534387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.